Showing results (181-190 of 589) with videos related to
Sort By:
Pageof 59
Cancers|December 10, 2021
Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer AnalysisDongyu Zhang, Neil J Shah, Michael Cook, et al.Cancer|September 4, 2009
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanomaJohn Glaspy, Michael B Atkins, Jon M Richards, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leakDiana C Gallagher, Rupal S Bhatt, Samir M Parikh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology GroupMichael B Atkins, Jessie Hsu, Sandra Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2002
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanomaMichael B Atkins, Jared A Gollob, Jeffrey A Sosman, et al.Journal for Immunotherapy of Cancer|January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinomaHollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.The Oncologist|April 16, 2021
Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II StudyCaroline A Nebhan, Douglas B Johnson, Ryan J Sullivan, et al.Journal for Immunotherapy of Cancer|May 22, 2020
COVID-19 and immune checkpoint inhibitors: initial considerationsRyan J Sullivan, Douglas B Johnson, Brian I Rini, et al.Journal of Neuro-Oncology|February 18, 2018
The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicityRifaquat Rahman, Alfonso Cortes, Andrzej Niemierko, et al.Journal of Translational Medicine|July 31, 2009
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanomaAntoni Ribas, John M Kirkwood, Michael B Atkins, et al.Pageof 59